Skip to main content

Renal Biomarkers Market 2018-2027: Growth Analysis, Development and Key Manufacturer Analysis

Press release   •   Jun 04, 2019 11:00 IST

The major factors which are expected to provide market growth are increase incidences of kidney disease, rise in geriatric population, the use of biomarkers in clinical and preclinical trials, loss of kidney function, increase in prevalence of chronic diseases, aging population and others. Additionally, increase in investment in research and development are anticipated to provide opportunities in market growth.

The report analyzes factors affecting renal biomarkers market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the renal biomarkers market in these regions.

Get PDF sample copy:

The biomarkers are measurable indicators of presence and severity of any disease that indicates the state of disease for which the therapeutic intervention is planned in accordance. The biomarkers are majorly used to diagnose the presence of any existing as well as developing disease. The renal biomarker checks the appropriate working of kidneys, and developing disease related to kidney by measuring blood and urine level. Biomarkers are needed to prevent the higher rate of kidney disorders and for prediagnosis.

The List of Companies

1. Abbott
2. F. Hoffmann-La Roche AG
3. Beckman Coulter Inc.
4. Siemens Healthcare Diagnostics Inc.
5. Thermo Fisher Scientific Inc.
6. Astute Medical Inc.
7. RenalSense Ltd
8. bioMérieux SA
9. Randox Laboratories Ltd.


The global renal biomarkers market is segmented on the basis of marker type, assay platform type, and application. Based on marker type, the market is segmented as creatinine, blood urea nitrogen (BUN), cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), and others. Based on assay platform type the market is segmented as enzyme linked immunosorbent assay (ELISA), enzymatic assay particle-enhanced turbidimetric immunoassay (PETIA), and others. On the basis of application, the renal biomarkers market is segmented into diagnosis and disease progression monitoring, and research.

Inquire for Discount:

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global renal biomarkers market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The renal biomarkers market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region. 

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.

Comments (0)

Add comment


By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.